23 results
Evaluation of intensive therapy for relapsed B-cell lymphoma with CNS localisation. Treatment includes:a. intrathecal administration of rituximab, B. combining R-DHAP with high dose methotrexate intravenously.The following endpoints will be…
The main objective of the study is to determine time to progression of the primary malignancy (locally advanced or metastatic) in patients treated with ILuP and pulmonary metastasectomy. Secondary objectives are to assess pulmonary toxicity by…
The primary objective is the Objective tumor response rate (RECIST). Secondary objectives are: duration of overall response, time to tumor progression (TTP), progression free survival (PFS), overall survival, toxicity profile, incidence of…
Primary objectives:Efficacy of bortezomib combined with DLI in patients with relapse myeloma following (non) myeloablative allo-SCT as measured by- response rate including percentage of complete remission according to EBMT criteria (appendix A)-…
To optimize a safe five-day intensive intravenous insulin treatment post stroke and to assess glucose profiles in patients with stroke and HG on admission, receiving standard continues enteral tube feeding.
Determine whether temozolomide given during radiation therapy followed by the combination of temozolomide and CCNU as adjuvant therapy results in an improvement in event-free survival compared to historical control cohorts.To further assess the…
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
The sequential application of chemotherapy and radionuclide treatment in patients with symptomatic osseous metastasized prostate cancer. Patients with more than one painful osseous metastasis will be randomized between 153Sm-EDTMP or docetaxel 3…
Primary: To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy (see Definitions).Subjects will be…
The primary objective of this study is:To determine the response rate [the combined complete response (CR) + partial response (PR) + minimal response (MR)] following treatment with BDR in patients with previously untreated WM.Secondary objectives…
The challenging aim of this three-year STREP project is to breakthrough with research that addresses the needs of those with dementia, particularly those with mild dementia in Europe. At about 2% of the elderly population, this comes to around 1,900…
The main goal of neoadjuvant therapy should be a pathological complete response (pCR), because pCR more accurately predicts improved patient outcome and prolonged survival. In the present study, pathological response will be evaluated by The Miller…
Primary objectives:To determine the objective tumor response (CR + PR) after 3 weeks of erlotinibSecondary objectives: To describe predictive markers for response:- radiological response (FDG-PET/CT)- EGFR mutations (HER1)To determine (diseasefree)…
Primary Objective: The primary objective of the study is to assess long-term safety of AMG 108 (125 mg, 250 mg) SC in subjects with RA previously enrolled in study 20050168.Secondary Objective(s): The secondary objectives of the study are:* To…
The first objective is to evaluate the safety of cetuximab in patients with scleroderma associated PAH. The secondary objective is to assess efficacy.
The primary objective is to gain experience with primary radiochemotherapy and to determine the locoregional response rate at 12 weeks after radiochemotherapy and after groin dissection for cN1,2 patients.
The aim of this study is to assess the clinical activity of BMS-275183 in patients who have failed prior treatment.
The objective of this open label phase IIa trial is to evaluate the efficacy and tolerability of a once a week dose of 200 mg R126638, for a maximum of 12 weeks, for the treatment of toenail onychomycosis.
Identification of low allergenic apple cultivars and breeding germplasmIdentification of chains in which low allergenicity is preserved and of the critical steps in the chain for preserving low allergenicity.
To evaluate safety and tolerability of AMG 531 in patients with low or intermediary-1 risk MDS and thrombocytopenia and to evaluate thrombocyte response at AMG 531 in these patients.